肝癌VEGF过表达的预后意义及作为生物标志物的潜力

王 硕晨, 任 宾*
青海大学;青海大学附属医院肝胆胰外科

摘要


肝癌是全球范围内发病率和死亡率极高的恶性肿瘤之一，其中肝细胞癌（Hepatocellular carcinoma，HCC）是最常见的肝癌类型。肝细胞癌中血管内皮生长因子（VEGF）的过表达与肿瘤进展密切相关，但其作为预后标志物的临床价值仍需系统评估。本研究旨在探讨VEGF过表达对肝癌患者预后的预测作用，并分析其作为靶向治疗疗效评估生物标志物的潜力。重点解决当前VEGF靶向治疗个体差异显著的问题，为克服耐药性和实现精准治疗提供理论依据。通过整合临床数据与分子特征，揭示VEGF在肝癌预后分层和治疗决策中的临床应用价值。
　　肝细胞癌（HCC）作为恶性程度高、预后差的常见恶性肿瘤[1]，其发生发展与血管内皮生长因子（VEGF）介导的异常血管生成密切相关。VEGF过表达不仅通过促进肿瘤血管新生支持HCC生长，还与肿瘤微环境特征性改变形成恶性循环，进而影响HCC的侵袭转移能力。临床证据显示，VEGF表达水平与HCC患者的不良病理特征（如血管侵犯、高复发率）及预后显著相关，使其成为潜在的独立预后标志物。同时，VEGF检测在指导靶向治疗选择及疗效监测方面展现出重要价值，推动HCC治疗策略从单一靶向药物向血管正常化联合治疗模式的转变。本文主要以VEGF过表达在肝癌中的预后意义及其作为生物标志物的潜在价值为主要探讨对象。

关键词


肝癌；血管内皮生长因子（VEGF）；预后；生物标志物

全文:

PDF


参考


[1]Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660IF: 503.1 Q1 . Epub 2021 Feb 4. PMID: 33538338.

[2]Zhang W, Sun L, Gao H, Wang S. Mechanism of the HIF-1α/VEGF/VEGFR-2 pathway in the proliferation and apoptosis of human haemangioma endothelial cells. Int J Exp Pathol. 2023 Oct;104(5):258-268. doi: 10.1111/iep.12485. Epub 2023 Jun 28. PMID: 37381118; PMCID: PMC10500167.

[3]Zhu Y, Liu R, Zhao X, Kang C, Yang D, Ge G. VEGF overexpression in transplanted NSCs promote recovery of neurological function in rats with cerebral ischemia by modulating the Wnt signal transduction pathway. Neurosci Lett. 2024 Feb 28;824:137668. doi: 10.1016/j.neulet.2024.137668. Epub 2024 Feb 7. PMID: 38331020.

[4]Zhao Y, Sun J, Jin L. The N6-Methyladenosine Regulator ALKBH5 Mediated Stromal Cell-Macrophage Interaction via VEGF Signaling to Promote Recurrent Spontaneous Abortion: A Bioinformatic and In Vitro Study. Int J Mol Sci. 2022 Dec 13;23(24):15819. doi: 10.3390/ijms232415819. PMID: 36555463; PMCID: PMC9785252.

[5]Budipramana K, Sangande F. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. Chem Biol Drug Des. 2024 May;103(5):e14534. doi: 10.1111/cbdd.14534. PMID: 38697951.

[6]胡雨婷，田莎，禚昭钦，等.肝癌血管生成与治疗研究进展[J].医学理论与实践，2024，37（09）：1474-1476+1483.DOI：10.19381/j.issn.1001-7585.2024.09.009.

[7]Tian Q, Zeng H, Lu QQ, Xie HY, Li Y. Diagnostic value of serum vascular endothelial growth factor and interleukin-17 in primary hepatocellular carcinoma. World J Gastrointest Surg. 2024 Sep 27;16(9):2934-2941. doi: 10.4240/wjgs.v16.i9.2934. PMID: 39351547; PMCID: PMC11438808.

[8]Subramanian S, Rajakumar HK. Unlocking the diagnostic potential of vascular endothelial growth factor and interleukin-17: Advancing early detection strategies for hepatocellular carcinoma. World J Gastrointest Surg. 2024 Nov 27;16(11):3639-3642. doi: 10.4240/wjgs.v16.i11.3639. PMID: 39649218; PMCID: PMC11622092.

[9]胡灵溪，李妹，付艺伟，等.血清血管内皮生长因子对肝动脉化疗栓塞单独/联合靶免治疗在中晚期肝癌临床疗效中的评估价值[J].中国全科医学，2024，27（32）：4033-4039.

[10]杨锦锋，曾荣耀.血管内皮生长因子和缺氧诱导因子-1α的表达与原发性肝癌患者临床病理特征及预后的关系[J].中国慢性病预防与控制，2020，28（12）：924-927.DOI：10.16386/j.cjpccd.issn.1004-6194.2020.12.010.

[11]Guo LY, Zhu P, Jin XP. Association between the expression of HIF-1α and VEGF and prognostic implications in primary liver cancer. Genet Mol Res. 2016 May 9;15(2). doi: 10.4238/gmr.15028107. PMID: 27173353.

[12]Miao YD, Tang XL, Wang JT, Mi DH. Prognostic role of expression of angiogenesis markers in hepatocellular carcinoma: A bioinformatics analysis. World J Gastroenterol. 2022 Aug 14;28(30):4221-4226. doi: 10.3748/wjg.v28.i30.4221. PMID: 36157115; PMCID: PMC9403432.

[13]李焕焕，聂志勇，吴涛，等.血清VEGF、AFP检测对原发性肝癌PD-1抑制剂联合抗血管生成疗效的预测价值[J].罕少疾病杂志，2024，31（02）：60-62.

[14]滕立勤，王思寅，董颖.血管内皮细胞生长因子表达变化对肝癌合并冠心病患者预后的评估价值研究[J].实用癌症杂志，2023，38（07）：1101-1104.

[15]Wei S, Li Z, Shi Q, Luan X, Yuan X, Li Y, Guo C, Wu X, Shi C, Di G. Collagenbinding vascular endothelial growth factor (CBDVEGF) promotes liver regeneration in murine partial hepatectomy. Mol Med Rep. 2022 Nov;26(5):326. doi: 10.3892/mmr.2022.12842. Epub 2022 Sep 7. PMID: 36069236; PMCID: PMC9727590.

[16]Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Edubilli TR, Mahrus S, Secrest MH, Shemesh CS, Yu N, Hack SP, Cha E, Gane E. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025 Feb;26(2):214-226. doi: 10.1016/S1470-2045(24)00679-X. Epub 2025 Jan 21. PMID: 39855251.

[17]Chen K, Shuen TWH, Chow PKH. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. Br J Cancer. 2024 Aug;131(3):420-429. doi: 10.1038/s41416-024-02684-w. Epub 2024 May 17. PMID: 38760445; PMCID: PMC11300599.

[18]Liu X, Huangfu Y, Wang J, Kong P, Tian W, Liu P, Fang C, Li S, Nie Y, Feng Z, Huang P, Shi S, Zhang C, Dong A, Wang W. Supramolecular Polymer-Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage-Reprogramming polyTLR7/8a Nanoregulator for Enhanced Anti-Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma. Adv Sci (Weinh). 2023 Aug;10(22):e2300637. doi: 10.1002/advs.202300637. Epub 2023 May 25. PMID: 37229748; PMCID: PMC10401096.

[19]Mi H, Ho WJ, Yarchoan M, Popel AS. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. Front Immunol. 2022 May 13;13:892250. doi: 10.3389/fimmu.2022.892250. PMID: 35634309; PMCID: PMC9136005.

[20]Dai H, Yan C, Huang W, Pan Y, Pan F, Liu Y, Wang S, Wang H, Ye R, Li Y. A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma. J Magn Reson Imaging. 2025 Feb;61(2):970-982. doi: 10.1002/jmri.29491. Epub 2024 Jun 22. PMID: 39777758; PMCID: PMC11706310.

[21]Shen H, Yu H, Li QY, Wei YT, Fu J, Dong H, Cao D, Guo LN, Chen L, Yang Y, Xu Y, Wu MC, Wang HY, Chen Y. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin. 2022 Nov;43(11):2917-2928. doi: 10.1038/s41401-022-00907-5. Epub 2022 May 4. PMID: 35508720; PMCID: PMC9622738.

[22]Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG. Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. J Natl Cancer Inst. 2022 Sep 9;114(9):1301-1305. doi: 10.1093/jnci/djac051. PMID: 35288743; PMCID: PMC9468280.

[23]刘欢丽，姜秋颖.TACE联合抗血管生成药治疗肝癌的研究进展[J].现代肿瘤医学，2022，30（18）：3408-3411.

[24]Zhong Y, Huo H, Dai S, Li S. Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis. Front Oncol. 2022 Aug 18;12:964779. doi: 10.3389/fonc.2022.964779. PMID: 36059696; PMCID: PMC9433548.

[25]Esteban-Fabró R, Willoughby CE, Piqué-Gili M, Montironi C, Abril-Fornaguera J, Peix J, Torrens L, Mesropian A, Balaseviciute U, Miró-Mur F, Mazzaferro V, Pinyol R, Llovet JM. Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clin Cancer Res. 2022 Jun 1;28(11):2449-2460. doi: 10.1158/1078-0432.CCR-21-2517. PMID: 35302601; PMCID: PMC9167725.

[26]Lu YC, Yang YC, Ma D, Wang JQ, Hao FJ, Chen XX, Chen YJ. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. Front Immunol. 2024 Nov 26;15:1471017. doi: 10.3389/fimmu.2024.1471017. PMID: 39660127; PMCID: PMC11628521.

[27]Hou C, Xiong B, Zhou L, Fei Y, Shi C, Zhu X, Xie T, Wu Y. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer. 2024 Mar 27;24(1):387. doi: 10.1186/s12885-024-12144-6. PMID: 38539150; PMCID: PMC10967172.


Refbacks

  • 当前没有refback。